Glioblastoma multiforme is the most common type of primary central nervous system tumor and is noted for its short survival and poor response to chemotherapeutic agents. Unfortunately, the relapse rate is very high, and there is no reference drug for second-line treatment. In this study, a patient was treated with the Soffi etti regimen. The induction phase was fotemustine 75 mg/m 2 at day 1 and day 8 and bevacizumab 10 mg/kg at day 1 and day 15. The maintenance phase was fotemustine 75 mg/m 2 and bevacizumab 10 mg/kg every 3 weeks for two cycles. Follow-up magnetic resonance imaging showed post-surgical changes at the left occipital level, without contrast enhancement, and toxic left leuko-encephalopathy post-treatment without mass effect and with no evidence of tumor residue. The patient then was maintained with bevacizumab monotherapy until it was withdrawn when pulmonary thromboembolism occurred. Following tumor regrowth, fotemustine was started again as maintenance therapy. The patient achieved stabilization of his disease until his death due to thromboembolic and infectious complications.
Introduction
Glioblastoma multiforme (GBM) is the most common type of primary central nervous system (CNS) tumor and is noted for its short survival and poor response to chemotherapeutic agents. [1] Adjuvant temozolomide and radiotherapy is the gold-standard treatment. [2] Unfortunately, the relapse rate is very high, and there is no reference drug for second-line treatment. [3] [4] [5] 
Case Report
This report describes the case of a 58-year-old patient with a history of hypertriglyceridemia and psoriasis who was admitted to the emergency department after a 4-day episode of disorientation to time and place, speech disturbance, 2/5 lack of muscle strength, right hemi-temporal blindness, and motor dysphasia. Chest, abdominal, and pelvic computed tomography was unremarkable. A brain magnetic resonance imaging (MRI) showed an oval left parieto-occipital lesion with the anteroposterior diameter of 27 mm, nodular contrast medium enhancement and white matter edema. In February 2011, the lesion was resected and was diagnosed as a WHO grade 4 GBM, with a 30% mind bomb E3 ubiquitin-ligase 1 proliferation index.
In March 2011, external radiotherapy (total dose 60 Gy, fractioned in 2 Gy/day) was started with concomitant temozolomide at 75 mg/m 2 /day, followed by temozolomide monotherapy (150 mg/m 2 for 5 days each 28 day circle in the fi rst cycle, and 200 mg/m 2 in the second cycle). Thereafter, an episode of gait imbalance with motor disturbance of the right upper limb occurred.
Three months after fi nishing radiotherapy, a brain MRI showed a cystic left parieto-occipital lesion measuring 40 mm × 40 mm × 30 mm, and edema. This MRI suggested tumor relapse [ Figure 1a ].
The patient rejected surgery and chemotherapy according to the Soffi etti et al. [6] regimen was started. The induction phase was fotemustine 75 mg/m 2 at day 1 and day 8 and bevacizumab 10 mg/kg at day 1 and day 15, followed by an interval of 3 weeks, and maintenance phase: fotemustine 75 mg/m 2 and bevacizumab 10 mg/kg, every 3 weeks for two cycles. Follow-up MRI showed post-surgical changes at the left occipital level, without contrast enhancement, toxic left leuko-encephalopathy post-treatment, without mass effect and with no evidence of tumor residue [ Figure 1b ]. There was a clinical response and from a radiological point of view, the mass had disappeared and there was no contrast enhancement (Response Assessment in Neuro-Oncology criteria were used to assess this). [7] The patient was discharged on a physiological replacement dose of corticosteroids and maintenance bevacizumab monotherapy. In April 2012, pulmonary thromboembolism occurred, and the bevacizumab was withdrawn. Low molecular weight heparin treatment was initiated. Two months later, repeat MRI showed a 2.5 cm enhancement area in the surgical site, suggesting tumor relapse. In June 2012, fotemustine was restarted as monotherapy at 75 mg/m 2 every 3 weeks (two cycles). In August 2012, MRI showed tumor stabilization. In November 2012, the patient suffered bronchoaspiration and unfortunately died.

Discussion
Fotemustine is a third-generation nitrosourea with alkylating cytotoxic activity and high lipophilicity that allows it to cross the blood-brain barrier. It achieves therapeutic levels in the CNS and has proven antitumor activity, either as monotherapy or in combination. [5, [8] [9] [10] Bevacizumab is a humanized monoclonal antibody that inhibits vascular endothelial growth factor and has activity in distinct tumors like GBM, either in monotherapy or combination with irinotecan. [11, 12] The combination of these two drugs has shown promising results. Soffi etti et al. [6] published the results of a phase II study in which fotemustine and bevacizumab were combined according to the following scheme: induction phase ( fotemustine 75 mg/m 2 at day 1 and day 8, and bevacizumab 10 mg/kg at day 1 and day 15); followed by an interval of 3 weeks, and maintenance phase (fotemustine 75 mg/m 2 and bevacizumab 10 mg/kg, every 3 weeks) until tumor progression, unacceptable toxicity, or withdrawal of consent. The combination of these two drugs showed promising results: overall response rate was 52%, and a signifi cant neurologic improvement was observed in 60% of symptomatic patients. Progression-free survival at 6 months was 42.6%, and overall survival at 6 months was 75.9%. Median progression-free survival was 5.2 months, and median overall survival was 9.1 months. Toxicity [6] with this regimen was predictable and manageable; grade 1 or 2 appeared in the majority of patients. Neutropenia (13%), thrombocytopenia (9%), wound dehiscence (5.5%), and deep venous thrombosis (4%) are the main grade 3 toxicities. Pulmonary embolism appeared as grade 4 toxicity in 4% of patients. These results encouraged us to use this therapeutic regimen in our patient.
The early initial progression, occurring shortly after the second adjuvant temozolomide cycle, made us consider a scheme that could achieve a high rate of disease control. The outstanding response obtained at 4 months of treatment with fotemustine plus bevacizumab, without radiological evidence from the pre-existing tumor mass, prompted us to continue with bevacizumab maintenance. [12] When this patient had received temozolomide monotherapy, he presented with instability and vertiginous symptoms. During bevacizumab and fotemustine therapy, the neurological symptoms disappeared. The withdrawal of bevacizumab after 7 months of treatment, due to pulmonary thromboembolism, caused a relapse of the disease. Nonetheless, the patient achieved stabilization of the disease from reintroduction of fotemustine until his death due to thromboembolic and infectious complications.
We consider this case interesting because treatment with bevacizumab plus fotemustine achieved rapid response, in 4 months, in a patient with rapid progression to fi rst-line treatment. Furthermore, it is notable because the patient responded to treatment with fotemustine after the progression that occurred following withdrawal of bevacizumab maintenance.
We consider that this combination scheme should be tested in further clinical trials. Due to the promising results reported by Soffi etti et al., and confi rmed by our own clinical experience, fotemustine should be considered as rescue treatment for relapsed GBM. 
